Lexington, Mass., USA - September 5, 2012, Lexington, Mass., USA - Pulmatrix, a clinical stage biotechnology company, announced the appointment of Robert Clarke as chief executive officer.
Article continues below
Mr. Clarke was promoted to CEO of Pulmatrix after serving as the company’s Chief Scientific Officer and Vice President of Research and Development.
Joining Pulmatrix in 2004 as the first Ph.D. level scientist, his role evolved to oversight of research and development efforts.
Previous to Pulmatrix, he was an Associate Director of Life Sciences at Alkermes, focused mainly on developing inhaled therapeutic products.
Mr. Clarke holds a B.Sc. in Biomedical Engineering from Boston University, has his Ph.D. in Physiology from Johns Hopkins University, and completed his postdoctoral training in Respiratory Biology at Brigham and Women’s Hospital and Harvard University.
Mr. Clarke has also been appointed to the company’s board of directors.
Mr. Clarke has more than a dozen years industry experience and more than 20 years total experience focused on pulmonary drug delivery and the role of inhaled particles in respiratory biology and medicine, leading to co-authorship of more than 80 chapters, papers, and abstracts.
Mr. Clarke succeeds Robert Connelly who has left Pulmatrix to lead a start-up company WikiCell Designs but he will continue to serve on the board of directors for Pulmatrix.
Mr. Connelly has 30 years of experience in the life sciences sector including the last 20 years in entrepreneurial pursuits.
He joined Pulmatrix in January of 2008 and led the company’s efforts to raise venture capital funding, conduct seven clinical trials, and introduce a novel drug delivery platform.
Prior to joining Pulmatrix, Mr. Connelly was the founding CEO and first employee of Domantis Limited, a biotechnology company.
He joined Pulmatrix after selling Domantis to Glaxo SmithKline, and prior to Domantis, he spent six years with Bioveris (formerly IGEN, acquired by Roche) as Senior Vice President of Sales and Marketing and General Manager of IGEN's Life Sciences unit.
Mr. Connelly spent the first 11 years of his career with Abbott Laboratories in sales, marketing, and management positions. ■